Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $6.75

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.80.

CMPX has been the topic of several recent analyst reports. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. D. Boral Capital assumed coverage on Compass Therapeutics in a research note on Monday, December 23rd. They issued a “buy” rating and a $32.00 price target on the stock. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Monday, September 16th.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the third quarter valued at about $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter valued at about $30,000. XTX Topco Ltd acquired a new position in Compass Therapeutics during the 3rd quarter valued at about $37,000. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics in the second quarter worth approximately $41,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Trading Down 3.9 %

NASDAQ CMPX opened at $1.46 on Monday. The firm has a market capitalization of $200.88 million, a PE ratio of -3.95 and a beta of 0.89. The business’s 50-day moving average price is $1.60 and its two-hundred day moving average price is $1.42. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.